Search

Thanks to all who came out to hear from Dr. Gina Suh and John Haverty for PHAVES #20 last week! Gina and John graciously shared their combined 'doctor-patient experience' with phage therapy — such an enlightening session! Recording now avai

BCM TAILOR Labs created a video that explains how clinicians can apply for expanded access or compassionate-use approval of phage therapy in the US through the FDA.

A new ESCMID Study Group that will deal with phage therapy has been created: the ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA). ESGNTA aims to explore non-traditional antibacterials including phage and phage-related

You can now watch the recording of PHAVES #19: Phage therapy for difficult-to-treat infections in children, with Dr. Ameneh Khatami here on the Phage Directory YouTube channel — PHAVES playlist. Thanks to everyone who came out for this even

The FDA's Center for Biologics Evaluation and Research and NIH's NIAID have announced a public workshop entitled “Science and Regulation of Bacteriophage Therapy.” The purpose of the public workshop is to exchange information with the medi

Rebekah Dedrick (University of Pittsburgh) and colleagues published a new paper in Nature Medicine on how antibody-mediated neutralization limited phage treatment of a pulmonary M. abscessus infection. They used the same phages that worked

We are urgently seeking Mycobacterium abscessus (smooth colony) phages for a patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strain - By receiving the strain and testing your phages -

We are urgently seeking Mycobacterium abscessus (smooth colony) phages for a patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strain - By receiving the strain and testing your phages -

PHAVES #19 will be a seminar by Dr. Ameneh Khatami, who is a senior lecturer in Child and Adolescent Health for the University of Sydney, based at The Children’s Hospital at Westmead, where she also works as a paediatric infectious diseases

PHAVES #19 will be a seminar by Dr. Ameneh Khatami, who is a senior lecturer in Child and Adolescent Health for the University of Sydney, based at The Children’s Hospital at Westmead, where she also works as a paediatric infectious diseases

Apurva Virmani Johri (Vitalis Phage Therapy, India) and colleagues published a case report in Frontiers in Pharmacology on phage therapy for treatment of chronic bacterial prostatitis. Significant improvements in symptoms and re-testing of

Adaptive Phage Therapeutics will be collaborating with Oyster Point Pharma (Nasdaq: OYST) to develop therapies to target multiple opthalmic diseases using APT’s PhageBank™ technology.

Adaptive Phage Therapeutics dosed the first patient in their phase 1/2 study to evaluate their PhageBank™ technology as a treatment for UTIs.

Saartje Uyttebroek (UZ Leuven & KU Leuven) and colleagues published a new review in Antibiotics showing the potential role of phages in the treatment of recalcitrant chronic rhinosinusitis. They also discuss considerations for implementing

PHAVES #18 will be a seminar by Rob McBride, co-founder of Felix Biotechnology, on Tues, June 8, 5PM Pacific time. Rob will give a talk on 'Using machine learning to design phages with enhanced therapeutic features'. Small group networking

PHAVES #18 will be a seminar by Rob McBride, co-founder of Felix Biotechnology, on Tues, June 8, 5PM Pacific time. Rob will give a talk on 'Using machine learning to design phages with enhanced therapeutic features'. Small group networking

PhageSuisse will host its third webinar on June 1st at 19h00, entitled "phageSuisse meets industry" with Dr. Frenk Smrekar from JAFRAL and Dr. Lorenzo Corsini from PhagoMed.

Wondering whether collecting and studying phages is worth your while? Here's a new article in Cystic Fibrosis News Today that remembers Mallory Smith, a young woman who phages could have saved, if they'd only been accessible a few days earl

Tristan Ferry (Hospices Civils de Lyon) and colleagues published a new case report in Frontiers in Medicine describing the combination of arthroscopic “Debridement Antibiotics and Implant Retention” (DAIR) with local injection of personaliz

Adaptive Phage Therapeutics (APT), a clinical-stage US biotech company, just closed a $40.75 million Series B investment round led by Deerfield Management Company (and also including Mayo Clinic). This will enable APT to accelerate clinical